|
|
Prepublished online as a Blood First Edition Paper on January 16, 2003; DOI 10.1182/blood-2002-08-2349.
Previous Article | Table of Contents | Next Article 
Blood, 1 May 2003, Vol. 101, No. 9, pp. 3495-3500
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Brief report
Role of the MyD88 transduction signaling pathway in endothelial
activation by antiphospholipid antibodies
Elena Raschi,
Cinzia Testoni,
Daniela Bosisio,
Maria O. Borghi,
Takao Koike,
Alberto Mantovani, and
Pier
Luigi Meroni
From the Istituto di Ricovero e Aura a Carattere
Scientifico (IRCCS) Istituto Auxologico Italiano, Allergy and
Clinical Immunology Unit, Milan, Italy; Mario Negri
Institute, Department of Immunology and Cell Biology, Milan,
Italy; University of Milan, Department of Internal
Medicine, Italy; Okkaido University School of Medicine,
Department of Medicine II, Sapporo, Japan; and University
of Milan, Department of Pathology, Italy.
Antiphospholipid syndrome (APS) is an autoimmune disease
characterized by the persistent presence of antiphospholipid antibodies (aPLs) and recurrent thrombosis or fetal loss. The thrombophilic state
has been partially related to the induction of a proinflammatory and
procoagulant endothelial cell (EC) phenotype induced by
anti- 2-glycoprotein I ( 2-GPI) antibodies
that bind 2-GPI expressed on the EC surface. Anti- 2-GPI antibody binding has been shown to induce
nuclear factor- B (NF- B) translocation leading to a
proinflammatory EC phenotype similar to that elicited by interaction
with microbial products (lipopolysaccharide [LPS]) and
proinflammatory cytokines (interleukin 1 [IL-1 ], tumor necrosis
factor [TNF- ]). However, the upstream signaling events are not
characterized yet. To investigate the endothelial signaling cascade
activated by anti- 2-GPI antibodies, we transiently
cotransfected immortalized human microvascular endothelial cells
(HMEC-1) with dominant-negative constructs of different components of
the pathway ( TRAF2, TRAF6, MyD88) together with reporter genes
(NF- B luciferase and pCMV- -galactosidase). Results showed that
both human anti- 2-GPI IgM monoclonal antibodies as well
as polyclonal affinity-purified anti- 2-GPI IgG
display a signaling cascade comparable to that activated by LPS or
IL-1. TRAF6 and MyD88 significantly abrogate antibody-induced as
well as IL-1- or LPS-induced NF- B activation, whereas TRAF2
(involved in NF- B activation by TNF) does not affect it. Moreover,
anti- 2-GPI antibodies and LPS followed the same time
kinetic of IL-1 receptor-activated kinase (IRAK) phosphorylation,
suggesting an involvement of the toll-like receptor (TLR) family. Our
findings demonstrate that anti- 2-GPI antibodies react
with their antigen likely associated to a member of the
TLR/IL-1 receptor family on the EC surface and directly induce activation.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Z. Romay-Penabad, M. G. Montiel-Manzano, T. Shilagard, E. Papalardo, G. Vargas, A. B. Deora, M. Wang, A. T. Jacovina, E. Garcia-Latorre, E. Reyes-Maldonado, et al.
Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo
Blood,
October 1, 2009;
114(14):
3074 - 3083.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K Oku, T Atsumi, M Bohgaki, O Amengual, H Kataoka, T Horita, S Yasuda, and T Koike
Complement activation in patients with primary antiphospholipid syndrome
Ann Rheum Dis,
June 1, 2009;
68(6):
1030 - 1035.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Urbanus, R. Derksen, and P. de Groot
Platelets and the antiphospholipid syndrome
Lupus,
October 1, 2008;
17(10):
888 - 894.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
E Raschi, M. Borghi, C Grossi, V Broggini, S Pierangeli, and P. Meroni
Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome
Lupus,
October 1, 2008;
17(10):
938 - 943.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
E Cockrell, R. Espinola, and K. McCrae
Annexin A2: biology and relevance to the antiphospholipid syndrome
Lupus,
October 1, 2008;
17(10):
944 - 952.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kinev and R. Roubey
Tissue factor in the antiphospholipid syndrome
Lupus,
October 1, 2008;
17(10):
953 - 959.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Salmon and P. de Groot
Pathogenic role of antiphospholipid antibodies
Lupus,
May 1, 2008;
17(5):
405 - 411.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S Pierangeli, M. E Vega-Ostertag, E. Raschi, X. Liu, Z. Romay-Penabad, V. De Micheli, M. Galli, M. Moia, A. Tincani, M. O. Borghi, et al.
Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies
Ann Rheum Dis,
October 1, 2007;
66(10):
1327 - 1333.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C Hamid, K Norgate, D P D'Cruz, M A Khamashta, M Arno, J D Pearson, G Frampton, and J J Murphy
Anti-{beta}2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome
Ann Rheum Dis,
August 1, 2007;
66(8):
1000 - 1007.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Blank, L. Anafi, G. Zandman-Goddard, I. Krause, S. Goldman, E. Shalev, R. Cervera, J. Font, M. Fridkin, H.-J. Thiesen, et al.
The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model
Int. Immunol.,
July 1, 2007;
19(7):
857 - 865.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Satta, S. Dunoyer-Geindre, G. Reber, R. J. Fish, F. Boehlen, E. K. O. Kruithof, and P. de Moerloose
The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies
Blood,
February 15, 2007;
109(4):
1507 - 1514.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Giannakopoulos, F. Passam, S. Rahgozar, and S. A. Krilis
Current concepts on the pathogenesis of the antiphospholipid syndrome
Blood,
January 15, 2007;
109(2):
422 - 430.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Blank, I. Krause, L. Magrini, G. Spina, J. Kalil, S. Jacobsen, H. J. Thiesen, M. W. Cunningham, L. Guilherme, and Y. Shoenfeld
Overlapping humoral autoimmunity links rheumatic fever and the antiphospholipid syndrome
Rheumatology,
July 1, 2006;
45(7):
833 - 841.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M V. Ostertag, X Liu, V Henderson, and S S Pierangeli
A peptide that mimics the Vth region of {beta}2glycoprotein I reverses antiphospholipid-mediated thrombosis in mice
Lupus,
June 1, 2006;
15(6):
358 - 365.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
K. R. McCrae
Annexin and APS: the clot thickens
Blood,
June 1, 2006;
107(11):
4195 - 4196.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Cesarman-Maus, N. P. Rios-Luna, A. B. Deora, B. Huang, R. Villa, M. d. C. Cravioto, D. Alarcon-Segovia, J. Sanchez-Guerrero, and K. A. Hajjar
Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome
Blood,
June 1, 2006;
107(11):
4375 - 4382.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Vora, R. A. Asherson, and D. Erkan
Catastrophic Antiphospholipid Syndrome
J Intensive Care Med,
May 1, 2006;
21(3):
144 - 159.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
Y Shoenfeld, M Blank, R Cervera, J Font, E Raschi, and P-L Meroni
Infectious origin of the antiphospholipid syndrome
Ann Rheum Dis,
January 1, 2006;
65(1):
2 - 6.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Buttari, E. Profumo, V. Mattei, A. Siracusano, E. Ortona, P. Margutti, B. Salvati, M. Sorice, and R. Rigano
Oxidized {beta}2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 response
Blood,
December 1, 2005;
106(12):
3880 - 3887.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T Koike and T Atsumi
Antiphospholipid antibodies and cell activation: crucial role of p38 MAPK pathway
Lupus,
October 1, 2005;
14(10):
799 - 801.
[PDF]
|
 |
|

|
 |

|
 |
 
M. Isogawa, M. D. Robek, Y. Furuichi, and F. V. Chisari
Toll-Like Receptor Signaling Inhibits Hepatitis B Virus Replication In Vivo
J. Virol.,
June 1, 2005;
79(11):
7269 - 7272.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Simoncini, C. Sapet, L. Camoin-Jau, N. Bardin, J.-R. Harle, J. Sampol, F. Dignat-George, and F. Anfosso
Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome
Int. Immunol.,
April 1, 2005;
17(4):
489 - 500.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Wolberg and R. A. S. Roubey
Annexin A2: better left alone
Blood,
March 1, 2005;
105(5):
1845 - 1846.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Zhang and K. R. McCrae
Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-{beta}2 glycoprotein I antibodies
Blood,
March 1, 2005;
105(5):
1964 - 1969.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Shi, B. Giannakopoulos, G. M. Iverson, K. A. Cockerill, M. D. Linnik, and S. A. Krilis
Domain V of {beta}2-Glycoprotein I Binds Factor XI/XIa and Is Cleaved at Lys317-Thr318
J. Biol. Chem.,
January 14, 2005;
280(2):
907 - 912.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bohgaki, T. Atsumi, Y. Yamashita, S. Yasuda, Y. Sakai, A. Furusaki, T. Bohgaki, O. Amengual, Y. Amasaki, and T. Koike
The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-{beta}2Glycoprotein I antibodies
Int. Immunol.,
November 1, 2004;
16(11):
1633 - 1641.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Pierangeli
Antiphospholipid antibodies: a mosaic of pathogenic effects?
Blood,
November 1, 2004;
104(9):
2619 - 2620.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. E. Warkentin, W. C. Aird, and J. H. Rand
Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome
Hematology,
January 1, 2003;
2003(1):
497 - 519.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|